Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia

American Heart Journal

Volumn 162, Issue 4, 2011, Pages 708-716

  Dansky, Hayes M ^a   Bloomfield, Daniel ^a   Gibbons, Patrice ^a   Liu, Sherry ^a   Sisk, Christine McCrary ^a   Tribble, Diane ^a,d   McKenney, James M ^b   Littlejohn III, Thomas W ^c   Mitchel, Yale ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b National Clinical Research Inc   (United States)

^c Piedmont Medical Research   (United States)

^d Currently Employed at Aegerion Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MIXED HYPERLIPIDEMIA; MONOTHERAPY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIMARY HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

CHOLESTEROL ESTER TRANSFER PROTEINS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OXAZOLIDINONES; WITHHOLDING TREATMENT;

EID: 80053620685     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.07.010     Document Type: Article

References (14)

1. A.R. Tall Plasma cholesteryl ester transfer protein J Lipid Res 34 1993 1255 1274 (Pubitemid 23230305)
2. M.E. Brousseau, E.J. Schaefer, and M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N Engl J Med 350 2004 1505 1515 (Pubitemid 38477775)
3. E.A. Stein, E.M. Roth, and J.M. Rhyne Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial Eur Heart J 31 2010 480 488
4. D. Bloomfield, G.L. Carlson, and A. Sapre Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am Heart J 157 2009 352 360
5. C.P. Cannon, S. Shah, and H.M. Dansky Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
6. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122 (Pubitemid 350146106)
7. R. Krishna, M.S. Anderson, and A.J. Bergman Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914 (Pubitemid 350192656)
8. W.T.t. Friedewald, R.I. Levy, and D.S. Fredrickson Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge Clin Chem 18 1972 499 502
9. S.S. Eveland, D.P. Milot, and Q. Guo A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology Anal Biochem 368 2007 239 249 (Pubitemid 47198567)
10. R. Krishna, Bergman A.J., and Jin B. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Clin Pharmacol Ther 84 2008 679 683
11. R. Temple Government viewpoint of clinical trials of cardiovascular drugs Med Clin North Am 73 1989 495 509
12. R. Krauss, K. Wojnoonski, and J.C. Geaney Effects of the cholesteryl ester transfer protein inhibitor anacetrapib on lipoprotein subfractions Atherosclerosis Supplement 10 2009 e1442
13. M. Ranalletta, K.K. Bierilo, and Y. Chen Biochemical characterization of cholesteryl ester transfer protein inhibitors J Lipid Res 51 2010 2739 2752
14. E.A. Stein, E.S. Stroes, and G. Steiner Safety and tolerability of dalcetrapib Am J Cardiol 104 2009 82 91